Lo Sasso, B.; Giglio, R.V.; Vidali, M.; Scazzone, C.; Bivona, G.; Gambino, C.M.; Ciaccio, A.M.; Agnello, L.; Ciaccio, M.
Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine. Diagnostics 2021, 11, 1135.
https://doi.org/10.3390/diagnostics11071135
AMA Style
Lo Sasso B, Giglio RV, Vidali M, Scazzone C, Bivona G, Gambino CM, Ciaccio AM, Agnello L, Ciaccio M.
Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine. Diagnostics. 2021; 11(7):1135.
https://doi.org/10.3390/diagnostics11071135
Chicago/Turabian Style
Lo Sasso, Bruna, Rosaria Vincenza Giglio, Matteo Vidali, Concetta Scazzone, Giulia Bivona, Caterina Maria Gambino, Anna Maria Ciaccio, Luisa Agnello, and Marcello Ciaccio.
2021. "Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine" Diagnostics 11, no. 7: 1135.
https://doi.org/10.3390/diagnostics11071135
APA Style
Lo Sasso, B., Giglio, R. V., Vidali, M., Scazzone, C., Bivona, G., Gambino, C. M., Ciaccio, A. M., Agnello, L., & Ciaccio, M.
(2021). Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine. Diagnostics, 11(7), 1135.
https://doi.org/10.3390/diagnostics11071135